

The Significance of Biomarkers

Subhadra Rani Jena*

Department of Botany and Biotechnology, Ravenshaw University, Cuttack, Odisha, India

Editorial

The term “biomarker” can be described as biochemical, molecular, or cellular modifications that are detectable in organic media such as human cells, tissues, or fluids [1]. Biomarkers comprise tools that can assist in predicting the root, diagnosis, succession, and effect of treatment of disease. Biomarkers can also mirror the complete range of ailment as of the initial appearances to the fatal stages [2]. Biomarkers of all kinds are used by physicians and researchers to learn human diseases [3]. Principally, biomarkers can be alienated into two types; biomarkers of diseases that are used in the diagnosis and examining disease expansion and biomarkers of exposure that are used in the estimation of risk of disease [3]. Biomarkers are well-known for their applications in the diagnosis and managing of cancer, immunological, cardiovascular, and as well as neurological diseases. Neuroscientists employ brain, blood, nerves, cerebrospinal fluid, skin muscle and urine to gather data regarding neural disorders. There are several complicated biomarker-related technologies that are appropriate to identify biomarkers at the level of mRNA, proteins, genes in bio-samples. However, such biomarkers are yet to expand [4]. Nevertheless, biomarkers are also a suitable tool for analysis of the natural history and prognosis of illness and revealing possible methods associated with the disease pathogenesis, accounting for some of the outcome alterations of risk prediction. These benefits have immediate relevance to every kind of clinical examination, starting clinical trials to observational leanings in epidemiology. Biomarkers can solve classifications of populations based on the degree of susceptibility rather than depending on the chronological description of vulnerability; instead of depending on details of the family history of the disease, biomarkers will favor the stratification of a population based on a specific genotype. [5-7]. Biomarkers are essential to drug development; they're in fact dangerous, since we have to determine the effects of new drugs on the group at some point in the clinical trials. Drug development today has numerous troubles, and the chief problem is the failure rate. Therefore, to progress the rate of success rate and develop the effectiveness of drug expansion, we need an entire new invention of biomarkers that are more constructive and that can inform pharmacists earlier whether their drug may have toxicity or it might not be effective at all [8]. Comprehending the

correlation between quantifiable biological processes and clinical outcomes is essential to escalating our battery of treatments for every disease, and for intensifying our perceptive of normal, healthy physiology [9]. In the age of adapted medicine, biomarkers may occupy a deliberate position in hastening the turn down in neonatal mortality by merely evaluating the possibility of rising neonatal diseases, by employing personalized therapeutic treatment, and by foreseeing the clinical result. Yet, there is an urgent requirement to lessen the gap in interpreting recently attained information from bench to bedside [10].

References

1. Barbara S. Hulka. “Overview of biological markers. In: Biological markers in epidemiology.” *Am J Hum Biol* 3 (1990): 218-219.
2. Richard Mayeux. “Biomarkers: Potential uses and limitations.” *Neurotherapeutics* 1 (2004): 182-188.
3. Frederica P. Perera and Bernard I. Weinstein. “Molecular epidemiology: Recent advances and future directions.” *Carcinogenesis* 21 (2000): 517-524.
4. Paul C. Guest. “The importance of biomarkers: The required tools of the trade.” In: *Biomarkers and Mental Illness* 2016 (2016): 31-41.
5. Christian Rohlf. “Proteomics in neuropsychiatric disorders.” *Int J Neuropsychopharmacol* 4 (2001): 93-102.
6. Kathleen Merikangas. “Genetic epidemiology: Bringing genetics to the population-the NAPE Lecture 2001.” *Acta Psychiatr Scand* 105 (2002): 3-13.
7. Ulrich Müller and Manuel B. Graeber. “Neurogenetic diseases: molecular diagnosis and therapeutic approaches.” *J Mol Med* 74 (1996): 71-84.
8. <https://www.fda.gov/drugs/cder-biomarker-qualification-program/what-are-biomarkers-and-why-are-they-important-transcript>
9. Kyle Strimbu and Jorge A Tavel. “What are biomarkers?” *Current Opinion in HIV and AIDS* 5 (2010): 463-466.
10. Michele Mussap, Antonio Noto, Francesco Cibecchini and Vassilios Fanos. “The importance of biomarkers in neonatology.” *Semin Fetal Neonat Med* 18 (2013): 56-64.

How to cite this article: Subhadra Rani, Jena. “The Significance of Biomarkers.” *J Mol Biomark Diagn* 11 (2020): 432. doi: 10.37421/jmbd.2020.11.432

*Address for Correspondence: Jena SR, Department of Botany and Biotechnology, Ravenshaw University, Cuttack, Odisha, India, E-mail: jenasubhadra06@gmail.com

Copyright: © 2020 Jena SR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received 11 August 2020; **Accepted** 18 August 2020; **Published** 25 August, 2020